|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Sorafenib (SOR) in patients (pts) with advanced/recurrent uterine carcinoma (UCA) or carcinosarcomas (CS) 显示文摘 | Nimeiri H Oza A M Morgan R J | 2008 | J Clin Oncol2008，26，15： | 1 |
| 2 | A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia 显示文摘 | Nimeiri HS Oza AM Morgan ILl | 2010 | Gynecol Oncol2010，117，1： | 1 |
| 3 | A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia 显示文摘 | Nimeiri HS Oza AM Morgan RJ | 2010 | Gyneeol Oncol2010，117，1： | 1 |
| 4 | A phaseⅡstudy of sorafenib in advanced uterine carcinoma/carcinosarcoma:a trial of the Chicago,PMH,and California PhaseⅡConsortia显示文摘 | Nimeiri HS Oza AM Morgan RJ | 2010 | Gynecol On-col2010，117，1： | 1 |
| 5 | A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors:A trial of the ECOG-ACRIN Cancer Research Group(E2211)显示文摘 | KUNZ P L CATALANO P J NIMEIRI H S | 2015 | J Clin Oncol2015，33，15： | 1 |
| 6 | Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovar- ian, primary peritoneal, and fallopian tube eancer:a trial of the Chicago, PMH, and California Phase Ⅱ Consortia 显示文摘 | Nimeiri HS1 Oza AM Morgan RJ | 2008 | Crynecol Oncol2008，110，1： | 1 |
| 7 | Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia显示文摘 | Nimeiri H S Oza A M Morgan R J etal | 2008 | Gynecol Oncol2008，110，1： | 1 |
| 8 | Efficacy and safety of beva-cizumab plus erlotinib for patients with recurrent ovarian,primary peritoneal,and fallopian tube cancer:a trial of the Chicago,PMH,and California PhaseⅡConsortia显示文摘 | Nimeiri HS Oza AM Morgan RJ | 2008 | Gynecol Oncol2008，110，1： | 1 |
| 9 | Stiffness method for curved box girders at initial stress显示文摘 | BAZANT Z P NIMEIRI M | | 0，，10： | 1 |
| 10 | Efficacy and safety of beva- cizumab plus erlotinib for patients with recurrent ovarian,primary peritoneal, and fallopian tubecancer : A trial of the Chicago, PMH, and California Phase II consortia显示文摘 | Nimeiri HS Oza AM Morgan R J | 2008 | Gynecol Oncol2008，110，1： | 1 |
| 11 | A phase Ⅱ study of sorafenib in advauced uterine carcinoma/carcinosarcoma:a trial of the Chicago,PMH,and California Phase Ⅱ Consortia显示文摘 | Nimeiri HS Oza AM Morgan RJ | | 0，，： | 1 |
| 12 | Eficacy and safe-ty of bevacizumab plus erlotinib for patients with recur-rent ovarian,primary peritoneal,and fallopian tube canc-er:a trial of the Chicago,PMH,and California Phase 1IConsortia显示文摘 | Nimeiri HS Oza AM Morgan RJ | 2008 | Gynecol Oncol2008，110，1： | 1 |
| 13 | Efieaey and safety of bev- acizumab plus erlotinib for patients with recurrent ovarian, prima- ry peritoneal and fallopian tube cancer: a trial of the Chicago, PMH,and California Phase Ⅱ Consortia 显示文摘 | Nimeiri HS Oza AM Morgan RJ | 2008 | Gyneeol Oneol2008，110，1： | 1 |
| 14 | Efficacy and safety of bevaci- zumab plus erlotinib for patients with recurrent ovarian, primary peri- toneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase llConsortia 显示文摘 | Nimeiri HS Oza AM Morgan R J | 2008 | Gynecol Oncol2008，110，1： | 1 |
| 15 | Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian,primary peritoneal,and fallopian tube cancer:A trial of the Chicago,PMH,and California Phase Ⅱ Consortia显示文摘 | Nimeiri HS Oza AM Morgan RJ | 2008 | Gynecol Oncol2008，110，1： | 1 |
| 16 | Challenges with linezolid therapy and re- versible pancytopenia 显示文摘 | Nimeiri H Nemiary D | 2003 | Ann Hematol2003，82，8： | 1 |
| 17 | Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian,primary peritoneal,and fallopian tube cancer:a trial of the Chicago,PMH,and California Phase II Consortia显示文摘 | Nimeiri HS Oza AM Morgan RJ | | 0，，01： | 1 |
| 18 | Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase Ⅱ Consortia 显示文摘 | Nimeiri H S Oza A M Morgan R J | 2008 | Gyneeol Oncol2008，110，1： | 1 |
| 19 | Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian,primary peritoneal,and fallopian tube cancer:a trial of the Chicago,PMH,and California Phase II Consortia显示文摘 | Nimeiri HS Oza AM Morgan RJ | 2008 | Gynecol Oncol2008，110，1： | 1 |
| 20 | Radioembolisation for liver metastases: Results from a prospective 151 patient multi-institutional phase II study显示文摘 | Al B. Benson Jean-Francois Geschwind Mary F. Mulcahy William Rilling Gary Siskin Greg Wiseman James Cunningham Bonny Houghton Mason Ross Khairuddin Memon James Andrews Chad J. Fleming Joseph Herman Halla Nimeiri Robert J. Lewandowski Riad Salem | 2013 | European Journal of Cancer2013，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员